MNKD vs UTHR vs INSM vs RARE

For growth investors, Insmed Incorporated (INSM) is the stronger pick with 66.

7% revenue growth year-over-year, versus 10. 6% for United Therapeutics Corporation (UTHR). United Therapeutics Corporation (UTHR) offers the better valuation at 20. 4x trailing P/E (19. 4x forward), making it the more compelling value choice. Analysts rate MannKind Corporation (MNKD) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, United Therapeutics Corporation (UTHR) is the cheapest at 20.

4x versus MannKind Corporation at 177. 5x. On forward P/E, United Therapeutics Corporation is actually cheaper at 19. 4x.

Over the past 5 years, Insmed Incorporated (INSM) delivered a total return of +221.

7%, compared to -77. 2% for Ultragenyx Pharmaceutical Inc. (RARE). Over 10 years, the gap is even starker: INSM returned +793. 5% versus RARE's -59. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), United Therapeutics Corporation (UTHR) is the lower-risk stock at 0.

19β versus Ultragenyx Pharmaceutical Inc. 's 1. 42β — meaning RARE is approximately 640% more volatile than UTHR relative to the S&P 500.

By revenue growth (latest reported year), Insmed Incorporated (INSM) is pulling ahead at 66.

7% versus 10. 6% for United Therapeutics Corporation (UTHR). On earnings-per-share growth, the picture is similar: United Therapeutics Corporation grew EPS 13. 1% year-over-year, compared to -79. 4% for MannKind Corporation. Over a 3-year CAGR, MNKD leads at 51. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

United Therapeutics Corporation (UTHR) is the more profitable company, earning 41.

9% net margin versus -210. 5% for Insmed Incorporated — meaning it keeps 41. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: UTHR leads at 46. 9% versus -194. 0% for INSM. At the gross margin level — before operating expenses — UTHR leads at 87. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, United Therapeutics Corporation (UTHR) trades at 19.

4x forward P/E versus 217. 8x for MannKind Corporation — 198. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for INSM: 107. 2% to $217. 11.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, United Therapeutics Corporation (UTHR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

19), +410. 0% 10Y return). Both have compounded well over 10 years (UTHR: +410. 0%, RARE: -59. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: MNKD is a small-cap high-growth stock; UTHR is a mid-cap quality compounder stock; INSM is a mid-cap high-growth stock; RARE is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.